Monthly News Roundup - June 2022
Skyrizi Approved with On-Body Injector for Treatment of Crohn’s disease Skyrizi (risankizumab-rzaa) works to reduce inflammation by binding to excess interleukin-23 (IL-23), a cytokine involved in several immune-mediated conditions. In June,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 30, 2022 Category: Pharmaceuticals Source Type: news

How Changing Your Diet Could Have a Major Impact on Managing Lupus Symptoms
After Jewell Singletary was diagnosed with lupus, she developed rheumatoid arthritis as well—a common pairing, since both are autoimmune conditions—and had to use a cane to navigate her college campus. When she graduated, the now 38-year-old New Jersey resident decided to be more focused on supporting her health, in an effort to maintain her mobility as she began her career. She started in the kitchen. First to be tossed were sugary drinks, fried foods, and highly processed options, she says. Once she eliminated them, it didn’t take long before she could discard one more important item: her cane. [time-br...
Source: TIME: Health - June 29, 2022 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized Diet & Nutrition freelance healthscienceclimate Source Type: news

Episode 3: How Insurance Denials and Delays Affect Patients With Crohn's Episode 3: How Insurance Denials and Delays Affect Patients With Crohn's
Drs Peter Higgins and Frank Scott discuss the challenges of delays in care for patients with Crohn ' s disease, how insurance denials and delays harm patients, and what doctors can do to help.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 21, 2022 Category: Consumer Health News Tags: Gastroenterology InDiscussion Source Type: news

FDA Approves Skyrizi for Moderately to Severely Active Crohn Disease
MONDAY, June 20, 2022 -- Skyrizi (risankizumab-rzaa), an interleukin-23 inhibitor, has received U.S. Food and Drug Administration approval to treat moderately to severely active Crohn disease (CD) in adults, according to AbbVie. Approved dosing for... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 20, 2022 Category: Pharmaceuticals Source Type: news

MRI Index Can Predict Postop Recurrence in Crohn Disease
MONDAY, June 20, 2022 -- A magnetic resonance imaging (MRI) index has been developed and validated for predicting postoperative recurrence (POR) in Crohn disease (CD), according to a study published in the May issue of Clinical Gastroenterology and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 20, 2022 Category: Pharmaceuticals Source Type: news

FDA Approves Risankizumab (Skyrizi) for Crohn ’s Disease FDA Approves Risankizumab (Skyrizi) for Crohn ’s Disease
The approval is the third indication for the anti-interleukin 23 monoclonal antibody after approval for psoriatic arthritis earlier this year and plaque psoriasis in 2019.FDA Approvals (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - June 17, 2022 Category: Gastroenterology Tags: Gastroenterology News Alert Source Type: news

FDA OKs Risankizumab for Crohn's Disease
(MedPage Today) -- The FDA has approved risankizumab (Skyrizi), an interleukin (IL)-23 inhibitor, for the treatment of moderately to severely active Crohn's disease, AbbVie announced on Friday. The approval for Crohn's disease was based on phase... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - June 17, 2022 Category: American Health Source Type: news

Skyrizi (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults
Third approved indication for Skyrizi (risankizumab-rzaa) is supported by safety and efficacy data from two induction and one maintenance clinical trials evaluating Skyrizi in moderately to severely active Crohn ' s disease, ADVANCE, MOTIVATE and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 17, 2022 Category: Drugs & Pharmacology Source Type: news

Two Biologics Work Equally Well for Active Crohn's Disease Two Biologics Work Equally Well for Active Crohn's Disease
For adults with moderate to severe Crohn ' s disease who have never been on a biologic agent, treatment with monotherapy with adalimumab or ustekinumab appear to be equally effective, according to results of the head-to-head SEAVUE trial.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - June 16, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Biologics for Crohn's Go Head to Head
(MedPage Today) -- Ustekinumab (Stelara) or adalimumab (Humira) were similarly effective as induction or maintenance therapy for moderate to severe Crohn's disease, according to the randomized SEAVUE trial. In an intention-to-treat analysis involving... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - June 14, 2022 Category: Gastroenterology Source Type: news

Study Sees Strong Links Between Depression and Crohn's, Colitis
Researchers found that people with IBD were nine times more likely to develop depression than the general population, while their siblings who did not have IBD were nearly two times more likely to develop the mood disorder. (Source: WebMD Health)
Source: WebMD Health - June 6, 2022 Category: Consumer Health News Source Type: news

Study Uncovers Strong Links Between Depression and Crohn ’ s, Colitis
(Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - June 6, 2022 Category: Psychiatry Tags: Gastroenterology, Psychiatry, Rheumatology, News, Source Type: news

Crohn's Disease Biomarker Appears Years Ahead of Diagnosis Crohn's Disease Biomarker Appears Years Ahead of Diagnosis
Sign of immune disruption could complement other prodromal signs of early or aggressive Crohn ' s disease and point the way to new therapies.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - June 6, 2022 Category: Primary Care Tags: Gastroenterology News Source Type: news

Risankizumab Eases Moderate to Severe Crohn's Disease
(MedPage Today) -- Risankizumab (Skyrizi) was safe and effective for patients with moderate to severe Crohn's disease (CD), according to two phase III induction trials and a maintenance trial. All co-primary endpoints were met at week 12 for the... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - June 6, 2022 Category: Gastroenterology Source Type: news

Study Uncovers Strong Links Between Depression and Crohn's, Colitis
MONDAY, June 6, 2022 -- New research points to a compelling interplay between inflammatory bowel disease (IBD) and depression. IBD includes Crohn ' s disease and ulcerative colitis. In addition to the physical pain that these illnesses can inflict... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 6, 2022 Category: General Medicine Source Type: news